Skip to main content
Daily Report

Daily Cardiology Research Analysis

03/12/2025
3 papers selected
3 analyzed

Three impactful cardiology studies stood out today: a multinational ESC/EHRA consensus unified the definition and measurement of atrial fibrillation burden, a Circulation study uncovered an immunometabolic mechanism linking myeloid fatty acid metabolism and hematopoietic stem cells to HFpEF, and a JAMA Cardiology cohort showed food insecurity independently predicts incident cardiovascular disease over two decades.

Summary

Three impactful cardiology studies stood out today: a multinational ESC/EHRA consensus unified the definition and measurement of atrial fibrillation burden, a Circulation study uncovered an immunometabolic mechanism linking myeloid fatty acid metabolism and hematopoietic stem cells to HFpEF, and a JAMA Cardiology cohort showed food insecurity independently predicts incident cardiovascular disease over two decades.

Research Themes

  • Standardization of AF burden metrics for diagnosis, risk stratification, and trials
  • Immunometabolism and hematopoiesis driving HFpEF pathophysiology
  • Social determinants (food insecurity) as independent CVD risk factors

Selected Articles

1. Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction.

87.5Level IIICohort
Circulation · 2025PMID: 40071347

Using human samples and complementary mouse models, the authors show that cardiometabolic HFpEF is characterized by elevated circulating hematopoietic stem cells, niche remodeling, and maladaptive myeloid fatty acid metabolism that fuels systemic inflammation and diastolic dysfunction. Multi-omics and isotope tracing support a cell-intrinsic macrophage metabolic program as a causal driver.

Impact: This study uncovers a mechanistic axis linking myeloid fatty acid metabolism to hematopoietic activation and HFpEF, opening therapeutic avenues targeting immunometabolism. It integrates human translational data with rigorous in vivo and ex vivo validation.

Clinical Implications: While not immediately practice-changing, the work suggests potential biomarkers (circulating hematopoietic stem cells) and therapeutic targets (myeloid fatty acid metabolic pathways) for HFpEF, a condition with limited options.

Key Findings

  • Patients with cardiometabolic HFpEF exhibited elevated peripheral blood hematopoietic stem cells; this phenotype was conserved in a high-fat diet plus hypertension mouse model.
  • Hematopoietic stem cell proliferation was coupled with remodeling of the peripheral stem cell niche and increased expression of a macrophage adhesion molecule.
  • Macrophage fatty acid metabolism was implicated as a causal driver of systemic inflammation and diastolic dysfunction, supported by isotope tracing and ex vivo assays.

Methodological Strengths

  • Translational design integrating human samples with complementary mouse models
  • Multi-omics (single-cell RNA-seq), mass spectrometry, and isotope tracing to establish mechanism

Limitations

  • Some mechanistic links remain inferential in humans and require interventional validation
  • Assay-specific sample sizes and details are not provided in the abstract, limiting appraisal of power

Future Directions: Test pharmacologic or genetic modulation of myeloid fatty acid metabolism in HFpEF models and evaluate circulating hematopoietic stem cells as biomarkers in longitudinal human cohorts.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment options remain limited. The HFpEF syndrome is associated with a high comorbidity burden, including high prevalence of obesity and hypertension. Although inflammation is implicated to play a key role in HFpEF pathophysiology, underlying causal mechanisms remain unclear. METHODS: Comparing patient samples and animal models, we defined the innate immune response during HFpEF in situ and through flow cytometry and single-cell RNA sequencing. After identifying transcriptional and cell signatures, we implemented a high-fat diet and hypertensive model of HFpEF and tested roles for myeloid and hematopoietic stem cells during HFpEF. Contributions of macrophage metabolism were also evaluated, including through mass spectrometry and carbon labeling. Primary macrophages were studied ex vivo to gain insight into complementary cell-intrinsic mechanisms. RESULTS: Here we report evidence that patients with cardiometabolic HFpEF exhibit elevated peripheral blood hematopoietic stem cells. This phenotype was conserved across species in a murine mode of high-fat diet and hypertension. Hematopoietic stem cell proliferation was coupled to striking remodeling of the peripheral hematopoietic stem cell niche and expression of the macrophage adhesion molecule CONCLUSIONS: These findings identify a significant new stem cell signature of cardiometabolic HFpEF and support a role for myeloid maladaptive fatty acid metabolism in the promotion of systemic inflammation and cardiac diastolic dysfunction.

2. Atrial fibrillation burden in clinical practice, research, and technology development: a clinical consensus statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association.

77Level IIISystematic Review
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025PMID: 40073206

An ESC/EHRA multidisciplinary consensus defines AF burden as the percentage of recording time in AF over a specified monitoring window and requires continuous or near-continuous monitoring for valid comparisons. It recommends reporting the longest AF episode and calls for disease-specific thresholds, enabling harmonized clinical decisions, trials, and device development.

Impact: Standardizing AF burden will immediately influence trial design, risk stratification, anticoagulation decisions, and wearable/device analytics across cardiology and stroke care.

Clinical Implications: Adopt continuous monitoring and report AF burden (% time in AF) and longest episode duration consistently. Use the unified framework to interpret device-derived AF data and to design endpoints; define actionable thresholds prospectively in disease-specific cohorts.

Key Findings

  • Unified definition: AF burden is the proportion of time in AF (% of recording time) during a specified monitoring duration.
  • Validity requirement: continuous or near-continuous monitoring must accompany AF burden reporting for comparability.
  • Report the longest uninterrupted AF episode; define disease-specific actionable thresholds in future studies.
  • Framework spans definition, recording principles, clinical relevance, and implementation for clinics and trials.

Methodological Strengths

  • Modified Delphi methodology with international, multidisciplinary experts
  • Evidence synthesis translating to clear operational guidance for clinics and trials

Limitations

  • Consensus statements are not a substitute for empirical validation of thresholds
  • Heterogeneity in device technologies and patient populations requires future calibration

Future Directions: Prospective studies to establish disease- and outcome-specific AF burden thresholds; validation across device types and care settings; integration into risk models and anticoagulation decision pathways.

Atrial fibrillation (AF) is one of the most common cardiac diseases and a complicating comorbidity for multiple associated diseases. Many clinical decisions regarding AF are currently based on the binary recognition of AF being present or absent with the categorical appraisal of AF as continued or intermittent. Assessment of AF in clinical trials is largely limited to the time to (first) detection of an AF episode. Substantial evidence shows, however, that the quantitative characteristic of intermittent AF has a relevant impact on symptoms, onset, and progression of AF and AF-related outcomes, including mortality. Atrial fibrillation burden is increasingly recognized as a suitable quantitative measure of intermittent AF that provides an estimate of risk attributable to AF, the efficacy of antiarrhythmic treatment, and the need for oral anticoagulation. However, the diversity of assessment methods and the lack of a consistent definition of AF burden prevent a wider clinical applicability and validation of actionable thresholds of AF burden. To facilitate progress in this field, the AF burden Consensus Group, an international and multidisciplinary collaboration, proposes a unified definition of AF burden. Based on current evidence and using a modified Delphi technique, consensus statements were attained on the four main areas describing AF burden: Defining the characteristics of AF burden, the recording principles, the clinical relevance in major clinical conditions, and implementation as an outcome in the clinic and in clinical trials. According to this consensus, AF burden is defined as the proportion of time spent in AF expressed as a percentage of the recording time, undertaken during a specified monitoring duration. A pivotal requirement for validity and comparability of AF burden assessment is a continuous or near-continuous duration of monitoring that needs to be reported together with the AF burden assessment. This proposed unified definition of AF burden applies independent of comorbidities and outcomes. However, the disease-specific actionable thresholds of AF burden need to be defined according to the targeted clinical outcomes in specific populations. The duration of the longest episode of uninterrupted AF expressed as a time duration should also be reported when appropriate. A unified definition of AF burden will allow for comparability of clinical study data to expand evidence and to establish actionable thresholds of AF burden in various clinical conditions. This proposed definition of AF burden will support risk evaluation and clinical treatment decisions in AF-related disease. It will further promote the development of clinical trials studying the clinical relevance of intermittent AF. A unified approach on AF burden will finally inform the technology development of heart rhythm monitoring towards validated technology to meet clinical needs.

3. Food Insecurity and Incident Cardiovascular Disease Among Black and White US Individuals, 2000-2020.

76Level IICohort
JAMA cardiology · 2025PMID: 40072427

In the CARDIA cohort (n=3616, mean follow-up 18.8 years), baseline food insecurity was associated with higher incident CVD (aHR 1.90; attenuated to 1.47 after socioeconomic adjustment). The association persisted across subgroups, supporting food insecurity as an independent social deprivation factor in CVD risk assessment.

Impact: This prospective, long-term study elevates food insecurity from a cross-sectional correlate to an independent predictor of incident CVD, informing risk stratification, screening, and policy interventions.

Clinical Implications: Incorporate food insecurity screening into cardiovascular risk assessment, particularly in primary care for midlife adults, and consider linkage to social support and nutrition assistance as part of preventive cardiology.

Key Findings

  • Among 3616 adults, 15% reported food insecurity at baseline; 255 incident CVD events occurred over a mean 18.8 years.
  • Food insecurity was associated with incident CVD (aHR 1.90, 95% CI 1.41-2.56), persisting after socioeconomic adjustment (aHR 1.47, 95% CI 1.08-2.01).
  • The association was observed across demographic subgroups, suggesting food insecurity as a robust social risk factor.

Methodological Strengths

  • Prospective cohort with nearly two decades of follow-up and adjudicated composite CVD outcomes
  • Diverse sample including Black and White participants with multivariable adjustment for socioeconomic factors

Limitations

  • Observational design cannot establish causality; residual confounding may persist
  • Food insecurity assessed at baseline; changes over time were not captured

Future Directions: Evaluate whether interventions that reduce food insecurity lower CVD incidence; integrate food insecurity into risk prediction models and health system screening workflows.

IMPORTANCE: Food insecurity is associated with prevalent cardiovascular disease (CVD), but studies have been limited to cross-sectional data. OBJECTIVES: To study whether food insecurity is associated with incident CVD and to determine whether this association varies by sex, education, or race. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted among US adults without preexisting CVD participating in the CARDIA (Coronary Artery Risk Development in Young Adults) study from 2000 to August 31, 2020. Data analysis was conducted from December 2022 to April 2024. EXPOSURE: Food insecurity, defined as endorsing limitations in household food variety and/or food quantity, assessed in the period 2000-2001. MAIN OUTCOMES AND MEASURES: The primary outcome was CVD events, consisting of fatal and nonfatal coronary heart disease, heart failure, stroke, transient ischemic attack, or peripheral arterial disease, identified annually through August 31, 2020. RESULTS: Of 3616 total participating adults, mean (SD) age was 40.1 (3.6) years, and 2027 participants (56%) were female. Of 3616 participants, 1696 (47%) self-reported Black race and 529 participants (15%) had food insecurity at baseline. Individuals with food insecurity were more likely to self-identify as Black and report lower educational attainment. The mean (SD) follow-up period was 18.8 (3.4) years, during which 255 CVD events occurred: 57 events (11%) in food-insecure participants and 198 events (6%) in food-secure participants over the study period. After adjusting for age, sex, and field center, food insecurity was associated with incident CVD (adjusted hazard ratio [aHR], 1.90; 95% CI, 1.41-2.56). The association persisted (aHR, 1.47; 95% CI, 1.08-2.01) after further adjustment for the socioeconomic factors of education, marital status, and usual source of medical care. CONCLUSIONS AND RELEVANCE: In this prospective cohort study among participants in the CARDIA study, food insecurity was associated with incident CVD even after adjustment for socioeconomic factors, suggesting that food insecurity may be an important social deprivation measure in clinical assessment of CVD risk. Whether interventions to reduce food insecurity programs can potentially alleviate CVD should be further studied.